WO2002003977A3 - Combinations of statins, estrogenic agents and optionally estrogens - Google Patents
Combinations of statins, estrogenic agents and optionally estrogens Download PDFInfo
- Publication number
- WO2002003977A3 WO2002003977A3 PCT/US2001/021085 US0121085W WO0203977A3 WO 2002003977 A3 WO2002003977 A3 WO 2002003977A3 US 0121085 W US0121085 W US 0121085W WO 0203977 A3 WO0203977 A3 WO 0203977A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- ethers
- statins
- combinations
- esters
- Prior art date
Links
- 239000000262 estrogen Substances 0.000 title abstract 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
- 229940011871 estrogen Drugs 0.000 title abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 2
- 150000002170 ethers Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical class 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical class *C#N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- SMYMDRJWEFCCCI-UHFFFAOYSA-N trichloro(trichloromethoxy)methane Chemical compound ClC(Cl)(Cl)OC(Cl)(Cl)Cl SMYMDRJWEFCCCI-UHFFFAOYSA-N 0.000 abstract 1
- WZEOZJQLTRFNCU-UHFFFAOYSA-N trifluoro(trifluoromethoxy)methane Chemical compound FC(F)(F)OC(F)(F)F WZEOZJQLTRFNCU-UHFFFAOYSA-N 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical class FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
This invention comprises methods of treating cardiovascular disorders and lowering blood LDL levels comprising administration of a statin, an estrogen and compound of the formulae (I or II): wherein Z is a moiety selected from the group of: (III) wherein: R1 is selected from H, OH or the C1-C12 esters or C1-C12 alkyl ethers thereof, benzyloxy, or halogen; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R2, R3, R4, R5, and R6 are H, OH or C1-C12 esters or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated ethers, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H1, R2 is not OH; Y is the moiety: (IV) R7 and R8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01950826A EP1359940A2 (en) | 2000-07-06 | 2001-06-29 | Combinations of statins, estrogenic agents and optionally estrogens |
| BR0112365-3A BR0112365A (en) | 2000-07-06 | 2001-06-29 | Combinations of statins, estrogens and optionally estrogens |
| AU2001271785A AU2001271785A1 (en) | 2000-07-06 | 2001-06-29 | Combinations of statins, estrogenic agents and optionally estrogens |
| MXPA02012896A MXPA02012896A (en) | 2000-07-06 | 2001-06-29 | Combinations of statins, estrogenic agents and optionally estrogens. |
| CA002414060A CA2414060A1 (en) | 2000-07-06 | 2001-06-29 | Combinations of statins, estrogenic agents and optionally estrogens |
| JP2002508432A JP2004502731A (en) | 2000-07-06 | 2001-06-29 | Combinations of statins, estrogens and optional estrogens |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21609600P | 2000-07-06 | 2000-07-06 | |
| US21618400P | 2000-07-06 | 2000-07-06 | |
| US60/216,184 | 2000-07-06 | ||
| US60/216,096 | 2000-07-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002003977A2 WO2002003977A2 (en) | 2002-01-17 |
| WO2002003977A3 true WO2002003977A3 (en) | 2003-09-04 |
Family
ID=26910656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2001/021085 WO2002003977A2 (en) | 2000-07-06 | 2001-06-29 | Combinations of statins, estrogenic agents and optionally estrogens |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1359940A2 (en) |
| JP (1) | JP2004502731A (en) |
| CN (1) | CN1468110A (en) |
| AU (1) | AU2001271785A1 (en) |
| BR (1) | BR0112365A (en) |
| CA (1) | CA2414060A1 (en) |
| MX (1) | MXPA02012896A (en) |
| WO (1) | WO2002003977A2 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1545206B1 (en) | 2002-07-24 | 2020-03-04 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
| US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| JP4889944B2 (en) | 2002-10-29 | 2012-03-07 | コロラド ステート ユニバーシティー リサーチ ファウンデーション | Use of equol to treat androgen-mediated diseases |
| US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| NZ779654A (en) | 2015-10-01 | 2024-12-20 | Olema Pharmaceuticals Inc | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs |
| HRP20221462T1 (en) | 2015-12-09 | 2023-01-20 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulators |
| ES2990061T3 (en) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Spirocyclic degronimers for the degradation of target proteins |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| ES2989988T3 (en) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Heterocyclic degronimers for the degradation of target proteins |
| CN109641874A (en) | 2016-05-10 | 2019-04-16 | C4医药公司 | C for target protein degradation3The glutarimide degron body of carbon connection |
| CN109789143A (en) | 2016-07-01 | 2019-05-21 | G1治疗公司 | Antiproliferative based on pyrimidine |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| CN110177554B (en) | 2017-01-06 | 2023-06-02 | G1治疗公司 | Combination Therapies Used to Treat Cancer |
| CA3052810A1 (en) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| BR112019027967A2 (en) | 2017-06-29 | 2020-07-14 | G1 Therapeutics, Inc. | isolated crystalline form b, pharmaceutical composition, method for treating a disorder, method of a compound or composition, and, process for producing crystalline form b. |
| CN113453679A (en) | 2018-12-20 | 2021-09-28 | C4医药公司 | Targeted protein degradation |
| CN118344370A (en) | 2019-12-20 | 2024-07-16 | C4医药公司 | Isoindolinone and indazole compounds for EGFR degradation |
| CN115279370B (en) | 2020-03-05 | 2025-01-10 | C4医药公司 | Compounds for targeted degradation of BRD9 |
| EP4192458A4 (en) | 2020-08-05 | 2024-09-04 | C4 Therapeutics, Inc. | COMPOUNDS FOR TARGETED RET DEGRADATION |
| CN119998285A (en) | 2022-08-03 | 2025-05-13 | 百时美施贵宝公司 | Compounds for modulating RET proteins |
| WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
| WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
| WO2025006753A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999059581A1 (en) * | 1998-05-15 | 1999-11-25 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens |
| WO1999059969A1 (en) * | 1998-05-15 | 1999-11-25 | American Home Products Corporation | Compositions comprising 2-phenyl-indole compounds and estrogen formulations |
-
2001
- 2001-06-29 BR BR0112365-3A patent/BR0112365A/en not_active IP Right Cessation
- 2001-06-29 MX MXPA02012896A patent/MXPA02012896A/en unknown
- 2001-06-29 CN CNA018150896A patent/CN1468110A/en active Pending
- 2001-06-29 AU AU2001271785A patent/AU2001271785A1/en not_active Abandoned
- 2001-06-29 EP EP01950826A patent/EP1359940A2/en not_active Withdrawn
- 2001-06-29 CA CA002414060A patent/CA2414060A1/en not_active Abandoned
- 2001-06-29 JP JP2002508432A patent/JP2004502731A/en active Pending
- 2001-06-29 WO PCT/US2001/021085 patent/WO2002003977A2/en not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999059581A1 (en) * | 1998-05-15 | 1999-11-25 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens |
| WO1999059969A1 (en) * | 1998-05-15 | 1999-11-25 | American Home Products Corporation | Compositions comprising 2-phenyl-indole compounds and estrogen formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1359940A2 (en) | 2003-11-12 |
| CN1468110A (en) | 2004-01-14 |
| JP2004502731A (en) | 2004-01-29 |
| WO2002003977A2 (en) | 2002-01-17 |
| BR0112365A (en) | 2003-05-13 |
| MXPA02012896A (en) | 2003-10-24 |
| CA2414060A1 (en) | 2002-01-17 |
| AU2001271785A1 (en) | 2002-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002003977A3 (en) | Combinations of statins, estrogenic agents and optionally estrogens | |
| WO2002003976A3 (en) | Combinations of bisphosphonates, estrogenic agents and optionally estrogens | |
| WO2002003992A3 (en) | Use of substituted indole compounds for treating prosthesis-related bone degeneration | |
| WO2002003986A3 (en) | Use of substituted indole compounds for treating breast disorders | |
| WO2002003988A3 (en) | Use of substituted indole compounds for treating neuropeptide y-related conditions | |
| WO2002003990A3 (en) | Use of substituted insole compounds for treating excessive intraocular pressure | |
| WO2002003989A3 (en) | Use of substituted indole compounds for treating sphincter incontinence | |
| WO2002003991A3 (en) | Use of substituted indole compounds for increasing nitric oxide synthase activity | |
| WO2002004418A3 (en) | Methods of inhibiting uterotrophic effects of estrogenic agents | |
| WO2002003987A3 (en) | Pharmaceutical compositions of estrogenic agents | |
| HRP20000726B1 (en) | Quinoline derivatives | |
| IL126339A (en) | Taxol derivatives | |
| EP1040823A3 (en) | Stable foam compositions | |
| WO2001009103A3 (en) | Imidazole antiproliferative agents | |
| DK1299348T3 (en) | Compounds and compositions for delivery of active agents | |
| MX9700883A (en) | Substituted quinazoline derivatives. | |
| NZ518296A (en) | N-phenyl-1,2-dihydro-2-oxo-quinoline-3-carboxamide derivatives and their use in the treatment of breast and prostatic cancer | |
| WO2002008217A3 (en) | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS | |
| CA2313122A1 (en) | Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents | |
| ES2122258T3 (en) | 4-AZAESTEROIDS 15 SUBSTITUTED. | |
| KR20000005379A (en) | Isatin derivatives as acetylcholinesterase inhibitors and analgesics | |
| EP1238973A4 (en) | Novel substituted tricyclic compounds | |
| CA2302943A1 (en) | Phthalazine compounds and therapeutic agents for erectile dysfunction | |
| NZ506011A (en) | Anti-tumour agents | |
| AU6220300A (en) | Benzofurylpiperazine serotonin agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/012896 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2001950826 Country of ref document: EP Ref document number: 2414060 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 018150896 Country of ref document: CN |
|
| WWP | Wipo information: published in national office |
Ref document number: 2001950826 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2001950826 Country of ref document: EP |